These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34910373)

  • 1. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.
    Serrano-Conde E; Leyva A; Fuentes A; de Salazar A; Chueca N; Pérez-Castro S; Regueiro B; Rojas A; Mendoza J; Rojas J; García F
    Transbound Emerg Dis; 2022 Sep; 69(5):2649-2655. PubMed ID: 34910373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
    Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
    J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
    van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD;
    Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.
    Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
    Microbiol Spectr; 2021 Dec; 9(3):e0056121. PubMed ID: 34851162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.
    Noori M; Nejadghaderi SA; Arshi S; Carson-Chahhoud K; Ansarin K; Kolahi AA; Safiri S
    Rev Med Virol; 2022 Mar; 32(2):e2277. PubMed ID: 34286893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
    Evans JP; Zeng C; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    Sci Transl Med; 2022 Mar; 14(637):eabn8057. PubMed ID: 35166573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection.
    Tyner HL; Burgess JL; Grant L; Gaglani M; Kuntz JL; Naleway AL; Thornburg NJ; Caban-Martinez AJ; Yoon SK; Herring MK; Beitel SC; Blanton L; Nikolich-Zugich J; Thiese MS; Pleasants JF; Fowlkes AL; Lutrick K; Dunnigan K; Yoo YM; Rose S; Groom H; Meece J; Wesley MG; Schaefer-Solle N; Louzado-Feliciano P; Edwards LJ; Olsho LEW; Thompson MG
    Clin Infect Dis; 2022 Aug; 75(1):e827-e837. PubMed ID: 34928334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients.
    Tolan NV; Sherman AC; Zhou G; Nabel KG; Desjardins M; Melanson S; Kanjilal S; Moheed S; Kupelian J; Kaufman RM; Ryan ET; LaRocque RC; Branda JA; Dighe AS; Abraham J; Baden LR; Charles RC; Turbett SE
    Microbiol Spectr; 2022 Apr; 10(2):e0021122. PubMed ID: 35311584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
    Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():946318. PubMed ID: 35928813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations.
    Jacobsen H; Strengert M; Maaß H; Ynga Durand MA; Katzmarzyk M; Kessel B; Harries M; Rand U; Abassi L; Kim Y; Lüddecke T; Metzdorf K; Hernandez P; Ortmann J; Heise JK; Castell S; Gornyk D; Glöckner S; Melhorn V; Kemmling Y; Lange B; Dulovic A; Marsall P; Häring J; Junker D; Schneiderhan-Marra N; Hoffmann M; Pöhlmann S; Krause G; Cicin-Sain L
    Sci Rep; 2022 Nov; 12(1):19858. PubMed ID: 36400804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum.
    Bates TA; Leier HC; Lyski ZL; McBride SK; Coulter FJ; Weinstein JB; Goodman JR; Lu Z; Siegel SAR; Sullivan P; Strnad M; Brunton AE; Lee DX; Adey AC; Bimber BN; O'Roak BJ; Curlin ME; Messer WB; Tafesse FG
    Nat Commun; 2021 Aug; 12(1):5135. PubMed ID: 34446720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
    Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
    Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
    Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-Related Differences in Neutralizing Antibody Responses against SARS-CoV-2 Delta and Omicron Variants in 151 SARS-CoV-2-Naïve Metropolitan Residents Boosted with BNT162b2.
    Lee B; Bae GE; Jeong IH; Kim JH; Kwon MJ; Kim J; Kim B; Lee JW; Nam JH; Huh HJ; Kang ES
    J Appl Lab Med; 2024 Jul; 9(4):741-751. PubMed ID: 38531067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine.
    Debes AK; Xiao S; Egbert ER; Caturegli P; Gadala A; Colantuoni E; Sitaras I; Pekosz A; Milstone AM
    Microbiol Spectr; 2022 Oct; 10(5):e0204622. PubMed ID: 36190405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.
    Lechmere T; Snell LB; Graham C; Seow J; Shalim ZA; Charalampous T; Alcolea-Medina A; Batra R; Nebbia G; Edgeworth JD; Malim MH; Doores KJ
    mBio; 2022 Apr; 13(2):e0379821. PubMed ID: 35297676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals.
    Dai YC; Lin YC; Ching LL; Tsai JJ; Ishikawa K; Tsai WY; Chen JJ; Nerurkar VR; Wang WK
    Microbiol Spectr; 2023 Aug; 11(4):e0408122. PubMed ID: 37428104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors.
    Chen RE; Gorman MJ; Zhu DY; Carreño JM; Yuan D; VanBlargan LA; Burdess S; Lauffenburger DA; Kim W; Turner JS; Droit L; Handley SA; Chahin S; Deepak P; O'Halloran JA; Paley MA; Presti RM; Wu GF; Krammer F; Alter G; Ellebedy AH; Kim AHJ; Diamond MS
    Med; 2021 Dec; 2(12):1327-1341.e4. PubMed ID: 34812429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines.
    Bartsch YC; Tong X; Kang J; Avendaño MJ; Serrano EF; García-Salum T; Pardo-Roa C; Riquelme A; Cai Y; Renzi I; Stewart-Jones G; Chen B; Medina RA; Alter G
    Sci Transl Med; 2022 Apr; 14(642):eabn9243. PubMed ID: 35289637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.